agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
![Serina Therapeutics logo](/files/LOGO/1708599-AGE.png)
Company profile
Ticker
SER
Exchange
Website
CEO
Michael West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
NeuroAirmid Therapeutics, Inc. • ReCyte Therapeutics, Inc. • Reverse Bioengineering, Inc. • UniverXome Bioengineering, Inc. • Canaria Transaction Corporation ...
IRS number
821436829
SER stock data
Latest filings (excl ownership)
S-1/A
IPO registration (amended)
14 Jun 24
S-8
Registration of securities for employees
14 Jun 24
8-K
Other Events
10 Jun 24
8-K
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
S-1
IPO registration
3 May 24
8-K
Changes in Registrant's Certifying Accountant
3 May 24
8-K
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
17 Apr 24
8-K
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
1 Apr 24
8-K
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.81 mm | 8.81 mm | 8.81 mm | 8.81 mm | 8.81 mm | 8.81 mm |
Cash burn (monthly) | (no burn) | (no burn) | 773.67 k | 274.22 k | 525.67 k | 278.75 k |
Cash used (since last report) | n/a | n/a | 2.01 mm | 712.17 k | 1.37 mm | 723.94 k |
Cash remaining | n/a | n/a | 6.80 mm | 8.09 mm | 7.44 mm | 8.08 mm |
Runway (months of cash) | n/a | n/a | 8.8 | 29.5 | 14.2 | 29.0 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 5,205 | 49.45 k | 20,206 |
29 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 1,173 | 11.14 k | 15,001 |
28 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 9,019 | 85.68 k | 13,828 |
23 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 2,371 | 22.52 k | 4,809 |
21 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 1,422 | 13.51 k | 1,522 |
21 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9.5 | 916 | 8.70 k | 2,438 |
20 May 24 | Bailey Gregory | Common Stock | Buy | Acquire P | No | No | 9 | 100 | 900.00 | 100 |
Press releases
Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson's Disease
15 May 24
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 May 24
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22 Mar 24